Concord Biotech Ltd (CONCORDBIO) Q1 FY27 Results Analysis: Revenue Surges 26%, EBITDA Margin Expands 189 bps

Concord Biotech Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 257.49 Cr (+26.23% YoY) and PAT growth of +32.84% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Revenue grew 26.23% YoY, beating management's FY27 aspiration of >18% growth. EBITDA margin expanded 189 bps YoY to 31.99% with operating leverage visible. Cost pressures from other expenses (+41% YoY) and inventory build (Rs.26.85 Cr) temper the otherwise strong quarter. USFDA ANDA approvals provide incremental growth catalysts.

Key Investment Insights

Key Positives

• Revenue grew 26.23% YoY to Rs.257.49 Cr, exceeding management's FY27 aspiration of >18% growth
• EBITDA margin expanded 189 bps YoY to 31.99%
• PAT attributable to owners grew 32.84% YoY to Rs.58.53 Cr
• USFDA ANDA approvals for Tofacitinib Tablets and Mycophenolate Mofetil Oral Suspension in June 2026
• Standalone revenue grew 27.71% YoY and PAT grew 43.74% YoY

Risk Factors

• Other expenses grew 41.02% YoY, the fastest-growing cost line, potentially reflecting injectable facility and Stellon Biotech setup costs
• Power and fuel costs rose 17.80% YoY and 16.67% QoQ, likely due to higher production volumes and/or tariff escalation
• Revenue declined 21.03% QoQ, reflecting typical lumpiness in API procurement cycles
• Inventory built by Rs.26.85 Cr, contradicting management's expectation of normalization within H1 FY27
• Subsidiaries (Stellon Biotech, Celliimmune) remain a net drag of Rs.2.67 Cr on consolidated PAT